Accreditation

Physicians
Scripps Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Scripps Health and SC Liver Research Consortium. Scripps Health is accredited by the ACCME to provide continuing medical education for physicians.

Scripps Health designates this live activity for a maximum of 7 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

About SC Liver Research Consortium (SCLRC) is an organization of physicians specializing in hepatology and gastroenterology clinical research. Our mission is to team research sponsors and our network of over 100 research sites together to provide faster, higher-quality research results compared to the “conventional” sponsor-site arrangement. We provide access to our scientific expertise in study design, efficient site selection, streamlined contract and budget negotiations, and management assistance throughout the clinical trial. www.scliver.com

About Scripps
Scripps Health, a nonprofit health care system based in San Diego, California, includes more than 2,600 affiliated physicians and over 13,000 employees at five acute-care hospital campuses, home health care services and a network of clinics, physician offices and outpatient centers. Scripps is committed to contributing to the future of medicine through its clinical research trials, graduate medical education and continuing medical education programs. More information can be found at www.scripps.org.

Educational Objectives

After attending this live activity, participants should be able to:

- Discuss the prevalence and incidence of acute and chronic hepatitis B and hepatitis C both in the general US population and in at-risk populations.
- Review the history, epidemiology, demographics, natural history, histology, immunology and pathophysiology of the viral infection.
- Discuss state-of-the-art diagnostic and treatment guidelines for both hepatitis B and C.
- Formulate and/or implement strategies for preventing, diagnosing, treating, and/or referring patients with HBV and/or HCV.
- Evaluate the multidisciplinary team approach to care of patients with hepatitis B and C.
- Establish a local network of practitioners for information sharing, referrals, etc.
- Improve the health of patients infected with the HBV and/or HCV virus.

Commercial Support
This course is supported, in part, by educational grants from industry, in accordance with ACCME accreditation Standards for Commercial Support. Appropriate acknowledgment will be given to all supporters at the time of the educational activity.
Hepatitis C

We will review the virology, genotypes, modes of infection of HCV and characteristics of the clinical illness caused by acute and chronic infections. Birth-cohort screening will be outlined. Tests for HCV, including PCR assays and genotyping, non-invasive testing for fibrosis, interpretations and indications for liver biopsies and the natural history of the disease will all be discussed. We will show how to initiate and monitor patients during treatment with all-oral antiviral treatments for hepatitis C, manage drug-drug interactions and deal with various patient populations including pre- and post-liver transplant, HIV-coinfected and end-stage renal disease patients. We will summarize the latest AASLD/IDSA guidelines using all-oral direct acting antiviral regimens for HCV.

Hepatitis B

We will summarize the history and discovery of HBV infection, discuss the modes of infection and prevalence of disease, and differentiate between acute and chronic infections. We will discuss protective antibodies, vaccination, complications of cirrhosis and hepatocellular carcinoma, tests for HBV, including PCR assays, genotyping and mutation analysis. We will include the latest AASLD guidelines for diagnosis, screening and treatment of chronic hepatitis B using nucleoside and nucleotide analogues for the treatment of chronic HBV including entecavir, TAF (tenofovir alafenamide), pegylated interferons and combinations of these regimens. We will also discuss new curative therapies for HBV in early development.

REGISTER ONLINE: www.scripps.org/hepbc

Questions: Scripps Conference Services & CME | 858-678-6400 | med.edu@scrippshealth.org